The European Pharmacopoeia (Ph. Eur.) is a publication that sets standards for the quality, purity, and strength of medicines in Europe. One of its key monographs is dedicated to tablets, a widely used dosage form for administering active pharmaceutical ingredients (APIs). In this article, we will focus on the Ph. Eur. monograph for tablets, specifically the one designated as "Tablets -0478-".
By adopting the standards and guidelines set out in the "Tablets -0478-" monograph, the pharmaceutical industry can ensure that tablets are produced and controlled to a high standard, ultimately benefiting patients and public health.
A 2020 European study found many tablets failed Ph. Eur. divisibility requirements. The Freedom of Information request regarding UK liothyronine tablets further demonstrates the practical consequences of non-compliance with these rules. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
The Ph. Eur. monograph for Tablets - 0478 plays a crucial role in ensuring the quality of tablet formulations. By following the guidelines set out in the monograph, manufacturers can ensure that their tablets meet the required standards for quality, purity, and strength. Regulatory authorities and control laboratories also use the monograph to evaluate the quality of tablets.
These are standard uncoated or coated tablets intended to release the active substance rapidly in the gastrointestinal tract. The European Pharmacopoeia (Ph
Friability testing determines the tablet's resistance to surface abrasion and fracture when subjected to mechanical shock. A sample of tablets is rotated in a drum (friabilitor) for a set number of revolutions. Monograph 0478 dictates that a maximum weight loss of is generally considered acceptable. E. Resistance to Crushing (2.9.8)
At the heart of oral solid dosage regulation lies . While it may seem like a generic entry, Monograph 0478 is the foundational legal text defining what a tablet is, how it must behave, and the tests it must pass before it is deemed safe for human use. Unlike active substance monographs (e.g., Paracetamol or Aspirin), this is a general monograph . It applies to all tablet formulations unless specifically waived or modified by an individual product monograph. In this article, we will focus on the Ph
These have separate monographs (e.g., 2066, 2067, etc.).
Disclaimer: This article is for informational purposes and does not substitute for consulting the official European Pharmacopoeia (current edition). Always refer to the legally binding Ph. Eur. text for specific acceptance criteria and validation requirements.